By Don Ross, Managing Director & Founder, HealthTech Capital
Early-stage investors in traditional healthcare companies are certainly having a tough time these days. Many biotech, diagnostic and medical device firms have simply become too risky, as the current uncertain FDA regulatory environment increases cost and time to exit. In fact, venture funding for these companies fell during the...